TARS

Tarsus Pharmaceuticals Inc

TARS, USA

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

https://www.tarsusrx.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
TARS
stock
TARS

Barclays Initiates Coverage on Tarsus Pharmaceuticals (TARS) with Overweight Rating | TARS Stock News GuruFocus

Read more →
TARS
stock
TARS

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Rating of “Moderate Buy” by Analysts Defense World

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$86.1111

Analyst Picks

Strong Buy

6

Buy

1

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

10.39

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-3.76 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-2.35 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

13.77 %

Low 5%

High 15%

Debt to Equity

-

Medium

0.60

Low 1

High 0.3

Investors

* Institutions hold a combined 98.50% of the total shares of Tarsus Pharmaceuticals Inc

1.

BlackRock Inc

(8.9832%)

since

2025/06/30

2.

RTW INVESTMENTS, LLC

(7.3712%)

since

2025/06/30

3.

Paradigm Biocapital Advisors LP

(7.05%)

since

2025/06/30

4.

Jennison Associates LLC

(5.8464%)

since

2025/06/30

5.

TANG CAPITAL MANAGEMENT LLC

(5.8151%)

since

2025/06/30

6.

Vanguard Group Inc

(5.4421%)

since

2025/06/30

7.

Morgan Stanley - Brokerage Accounts

(4.8697%)

since

2025/06/30

8.

HHG PLC

(4.2804%)

since

2025/06/30

9.

Deep Track Capital, LP

(4.1455%)

since

2025/06/30

10.

Vanguard Total Stock Mkt Idx Inv

(2.8181%)

since

2025/07/31

11.

The Toronto-Dominion Bank

(2.3735%)

since

2025/06/30

12.

Assenagon Asset Management SA

(2.3632%)

since

2025/06/30

13.

Lord, Abbett & Co LLC

(2.358%)

since

2025/06/30

14.

State Street Corp

(2.3236%)

since

2025/06/30

15.

Macquarie Group Ltd

(2.2477%)

since

2025/06/30

16.

Geode Capital Management, LLC

(2.2135%)

since

2025/06/30

17.

iShares Russell 2000 ETF

(2.21%)

since

2025/08/31

18.

Amvescap Plc.

(2.1995%)

since

2025/06/30

19.

Driehaus Capital Management LLC

(2.0764%)

since

2025/06/30

20.

D. E. Shaw & Co LP

(1.7131%)

since

2025/06/30

21.

Jennison SMid Cap Core Equity

(1.6174%)

since

2025/06/30

22.

PGIM Jennison Small Company A

(1.6174%)

since

2025/07/31

23.

Adage Capital Partners Gp LLC

(1.2863%)

since

2025/06/30

24.

Artisan Partners Limited Partnership

(1.2775%)

since

2025/06/30

25.

MEDICAL BioHealth EUR Acc

(1.2502%)

since

2025/06/30

26.

Macquarie Small Cap Growth C

(1.1328%)

since

2025/07/31

27.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9795%)

since

2025/07/31

28.

Lord Abbett Developing Growth A

(0.9624%)

since

2025/06/30

29.

RTW Biotech Opportunities Ord

(0.9506%)

since

2024/12/31

30.

Fidelity Small Cap Index

(0.922%)

since

2025/06/30

31.

Jennison Health Sciences Equity

(0.9067%)

since

2025/06/30

32.

PGIM Jennison Health Sciences Z

(0.9067%)

since

2025/07/31

33.

Artisan International Small-Mid Investor

(0.8489%)

since

2025/06/30

34.

Artisan Non-U.S. Small-Mid Growth Comp

(0.8489%)

since

2025/06/30

35.

iShares Russell 2000 Growth ETF

(0.8068%)

since

2025/08/31

36.

Janus Henderson Global Life Sciences

(0.7644%)

since

2025/06/30

37.

Janus Henderson Global Life Sciences D

(0.7644%)

since

2025/06/30

38.

Invesco Main Street Small Cap R6

(0.6575%)

since

2025/07/31

39.

APO Medical Opportunities R

(0.6545%)

since

2025/07/31

40.

Invesco Small Cap Core

(0.6464%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

EPS Estimate

Latest Release

Date

2025-09-30

EPS Actual

-0.3

EPS Estimate

-0.3645

EPS Difference

0.0645

Surprise Percent

17.6955%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4.5)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(3)
Economic Moat
Some Competitive Advantage(5.3)
GARP
Fair GARP(4.5)
Growth
Moderate Growth(3.5)
Momentum
No Momentum(3)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Moderate Quality(4)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.